Canada Markets closed

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.51-0.15 (-0.69%)
At close: 4:00PM EDT
21.51 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close21.66
Open21.71
Bid18.76 x 900
Ask21.50 x 900
Day's Range21.26 - 21.95
52 Week Range18.16 - 36.48
Volume299,311
Avg. Volume717,190
Market Cap1.291B
Beta (5Y Monthly)2.26
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateNov. 02, 2021 - Nov. 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.89
  • Zacks

    Company News for Sep 17, 2021

    Companies in The News Are: F,WYNN,LVS,MGNX

  • Motley Fool

    Why MacroGenics Stock Is Tanking Today

    Shares of MacroGenics (NASDAQ: MGNX) were tanking 26.4% lower as of 11:39 a.m. EDT on Thursday. The big decline came after the company announced data from a cohort in a phase 3 study evaluating margetuximab in combination with retifanlimab in treating gastroesophageal adenocarcinoma, cancer of the stomach and esophageal junction with the stomach. MacroGenics also announced preliminary data from a phase 1 clinical study evaluating MGC018 in treating advanced solid tumors.

  • GlobeNewswire

    MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021

    21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor shrinkage at first scanMedian duration of response was 10.3 months as of data cutoffMargetuximab plus retifanlimab was well tolerated with Grade 3 treatment-related adverse events (TRAEs) in 19% of patients; no Grade 4 TRAEs or treatment-related deathsFindings suggest this chemotherapy-free combination